Genentech Reports Mixed Results in Phase III IPATential150 Study Investigating Ipatasertib Combination Treatment for Prostate Cancer

Jun 26, 2020 | Challenging Results, Oncology, Urology

Genentech Reports Mixed Results in Phase III IPATential150 StudyStudying Ipatasertib Combination Treatment for Prostate Cancer

Genentech reported mixed results from the double-blind, placebo-controlled, randomized phase III IPATential150 trial of ipatasertib in combination with abiraterone and prednisone/prednisolone in adult male patients with asymptomatic or mildly symptomatic, previously untreated metastatic castration-resistant prostate cancer (mCRPC). The trial met its co-primary endpoint of radiographic progression-free survival (rPFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) and whose tumors had PTEN loss. In this patient group, ipatasertib in combination with abiraterone and prednisone/prednisolone provided a statistically significant reduction in the risk of disease worsening or death, compared to current standard of care (abiraterone and prednisone/prednisolone) plus placebo. The other co-primary endpoint of rPFS in the overall study population (intention-to-treat) was not met. The safety profile for the combination of ipatasertib and abiraterone was consistent with previous analyses and known risks.

Overall survival benefit and additional secondary endpoints are not yet mature. The trial will continue until the next planned analysis and data will be shared with health authorities.

The results of the IPATential150 study will be presented at an upcoming medical meeting.

About Ipatasertib

Ipatasertib is an oral, highly specific, investigational medicine designed to target and bind to all three isoforms of AKT (protein kinase B), which blocks the PI3K/AKT signaling pathway – a key driver of cancer cell growth and proliferation in prostate cancer. The PI3K/AKT pathway has also been implicated in resistance to anti-androgen therapy as androgen receptor (AR) inhibition is associated with an increase in AKT pathway activation. Functional loss of the tumor suppressor protein PTEN within the tumor, seen in approximately 40-60% of mCRPC patients, results in hyperactivation of the PI3K/AKT pathway and is associated with adverse outcomes such as increased tumor grade and stage, earlier biochemical recurrence after radical prostatectomy, metastasis, prostate-cancer-specific death, and androgen-independent progression.

Source: Genetech

0 Comments

Pin It on Pinterest